Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., develops and commercializes innovative immunotherapeutics for the treatment of cancer.
Dr. Xian-Qun Xie and his colleagues at the University of Pittsburgh have demonstrated that the ZZ domain of the p62/SQSTM1 protein is responsible for increased multiple myeloma cell growth and associated osteoclast mediated bone disease. Dr. Xie and colleagues have developed novel chemical compounds, such as OXS-4235, to inhibit osteoclastic bone destruction in multiple myeloma.
Multiple myeloma is a type of cancer that forms in white blood cells, and affects about 26,850 people annually in the U.S. causing about 11,240 deaths per year.
Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. Multiple myeloma is also characterized by destructive lytic bone lesions (rounded, punched-out areas of bone), diffuse osteoporosis, bone pain and the production of abnormal proteins, which accumulate in the urine.